RxDoctor Payments Data

Joseph Leonard, DO

Family Medicine · Parker, PANPI 1336462209

Payments from drug & device makers

$741in general payments, 2019–2025

Across 44 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$290
  • Grifols USA, LLC$126
  • Pfizer$125
  • GSK$114
  • Amarin Pharma, Inc.$19
  • Teva Pharmaceuticals USA, Inc.$18
  • plus $51 from 4 others

What the payments were for

  • Food & beverage$741100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$741 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$139,015
Medicare patients
337
Services billed
2,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban171$125,901
JardianceEmpagliflozin117$86,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$61,342
OzempicSemaglutide58$60,479
JanuviaSitagliptin Phosphate57$55,640
XareltoRivaroxaban80$51,730
TrulicityDulaglutide47$47,089
RybelsusSemaglutide44$46,220
MounjaroTirzepatide23$23,336
Spiriva RespimatTiotropium Bromide37$19,543
TradjentaLinagliptin27$16,984
Tresiba Flextouch U-200Insulin Degludec12$16,799
Breo ElliptaFluticasone/Vilanterol40$16,499
Xtampza ErOxycodone Myristate25$15,578
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$15,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$125,901171 claims
Novo NordiskOzempic, Rybelsus$290$106,699102 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$114$90,052151 claims
Johnson & JohnsonXarelto, Invokana$11$58,55291 claims
AstraZenecaFarxiga$12$14,62716 claims
Astellas Pharma US IncMyrbetriq$14$9,90614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Parker

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →